How GLP-1 medicines lower inflammation independent of weight loss
In clinical trials, GLP-1 receptor agonists lower markers of systemic inflammation. Much of this reduction tracks fat loss, but trials also show an earlier effect that does not depend on weight. Here is the science behind the gut-brain-immune axis, and what it means when the scale pauses.
· Biomeme Labs Clinical Team
Why hs-CRP doesn't tell the whole story: measuring the inflammation cycle
High-sensitivity C-reactive protein (hs-CRP) is medicine's gold-standard inflammation marker. But as a delayed liver protein, it captures only an echo of the alarm phase. Here is why measuring more of the inflammation cycle—including resolution—changes how we understand systemic health.
· Biomeme Labs Science Team
Why Transcriptomics? The Missing Cellular Layer in GLP-1 Care
What immune-cell gene activity adds to weight and routine laboratory measurements during GLP-1 therapy.
· Biomeme Labs Clinical Team